Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(R)-1,2,3,4-tetrahydro-1-naphthol + NAD+
3,4-dihydronaphthalen-1(2H)-one + NADH + H+
i.e. R-tetralol
-
-
?
(S)-1,2,3,4-tetrahydro-1-naphthol + NAD+
3,4-dihydronaphthalen-1(2H)-one + NADH + H+
i.e. S-tetralol
-
-
?
(S)-1,2,3,4-tetrahydro-1-naphthol + NADP+
3,4-dihydronaphthalen-1(2H)-one + NADPH + H+
i.e. S-tetralol
-
-
?
(S)-1-indanol + NAD+
2,3-dihydro-1H-inden-1-one + NADH + H+
-
-
-
?
(S)-camphorquinone + NADH + H+
? + NAD+
-
-
-
?
(S)-camphorquinone + NADPH + H+
? + NADP+
-
-
-
?
1-acenaphthenol + NAD+
acenaphthylen-1(2H)-one + NADH + H+
-
-
-
?
11beta-hydroxyandrost-5-ene-3,17-dione + NADPH
11beta,17beta-dihydroxyandrost-5-ene-3-one + NADP+
17-oxo steroids + NADPH
?
-
maintenance of balance between oxidized and reduced steroids in blood
-
-
?
17alpha-hydroxypregnenolone + NAD(P)+
17alpha-hydroxy-pregn-5-en-3,20-dione + NAD(P)H + H+
-
-
-
-
?
17alpha-hydroxypregnenolone + NAD(P)H + H+
17alpha-hydroxyprogesterone + NAD(P)+
-
-
-
-
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
-
-
?
17beta-hydroxy-5beta-androstane-3-one + NAD(P)H + H+
testosterone + NAD(P)+
-
-
-
?
2-cyclohexen-1-ol + NAD+
2-cyclohexen-1-one + NADH + H+
-
-
-
?
20alpha-dihydroprogesterone + NAD+
4-pregnen-3alpha,20beta-diol + NADH
-
-
-
-
r
20alpha-dihydroprogesterone + NADP+
4-pregnen-3alpha,20beta-diol + NADPH
-
-
-
-
r
20alpha-hydroxypregn-4-en-3-one + NADP+
progesterone + NADPH
-
-
-
r
3beta-hydroxy-16alpha,17alpha-epoxypregn-5-en-20-one + NAD(P)+
?
3beta-hydroxy-5alpha-androstan-17-one + NADP+
5alpha-androstane-3,17-dione + NADPH
-
-
-
?
3beta-hydroxyprogesterone + NADH + H+
? + NAD+
-
-
-
?
4-androsten-17beta-ol-3-one + NAD(P)+
4-androstene-3,17-dione + NAD(P)H + H+
17keto function is reduced. NADP+ is 3-5times less effective than NAD+
-
-
?
4-androsten-3,17-dione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
4-androstene-3alpha,17beta-diol + NAD+
? + NADH + H+
-
-
-
?
4-estrene-17beta-ol-3-one + NADP+
4-estrene-3,17-dione + NADPH
-
-
-
-
r
4-estrene-3,17-dione + NADPH
4-estrene-17beta-ol-3-one + NADP+
-
-
-
-
r
5-androsten-3beta-ol-17-one + NAD(P)+
5-androstene-3,17-dione + NAD(P)H + H+
NADP+ is 3-5times less effective than NAD+
-
-
?
5-androstene-3beta,17beta-diol + NAD+
? + NADH + H+
-
-
-
?
5-androstenedione + NADPH
5alpha-dihydrotestosterone + NADP+
-
isozyme 17beta-HSD3
-
-
r
5-pregnen-3beta-ol-20-one + NAD(P)+
5-pregnene-3,20-dione + NAD(P)H + H+
NADP+ is 3-5times less effective than NAD+
-
-
?
5alpha-androst-16-en-3-one + NADH
3beta-hydroxy-5alpha-androst-16-ene + NAD+
-
-
-
?
5alpha-androstan-3alpha-ol-17-one + NAD+
5alpha-androstan-3,17-dione + NADH + H+
-
-
-
?
5alpha-androstan-3beta-ol-17-one + NAD+
5alpha-androstan-3,17-dione + NADH + H+
-
-
-
?
5alpha-androstane-3alpha,17beta-diol + NAD+
?
-
-
-
?
5alpha-androstane-3beta,17beta-diol + NADP+
3beta-hydroxy-5alpha-androstan-17-one + NADPH
-
-
-
?
5alpha-dihydrotestosterone + NAD(P)H
5alpha-androstane-3beta,17beta-diol + NADP+
-
-
-
?
5alpha-dihydrotestosterone + NADH + H+
? + NAD+
-
-
-
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstane-3,17-dione + NADPH + H+
5alpha-pregnan-3alpha-ol-20-one + NAD+
5alpha-pregnan-3,20-dione + NADH + H+
-
-
-
?
5alpha-pregnan-3beta-ol-20-one + NAD(P)+
5alpha-pregnan-3,20-dione + NAD(P)H + H+
NADP+ and NADPH are 3-5times less effective than NAD+ and NADH
-
-
r
5alpha-pregnan-3beta-ol-20-one + NAD+
5alpha-pregnan-3,20-dione + NADH + H+
-
-
-
?
5alpha-pregnan-3beta-ol-20-one + NAD+
5alpha-pregnane-3,20-dione + NADH + H+
-
-
-
r
5alpha-pregnane-3,20-dione + NADH + H+
5alpha-pregnan-3beta-ol-20-one + NAD+
-
-
-
r
5beta-androstan-17beta-ol-3-one + NAD+
5beta-androstan-3,17-dione + NADH + H+
-
-
-
?
5beta-androstan-3alpha-ol-17-one + NAD+
5beta-androstan-3,17-dione + NADH + H+
-
-
-
?
5beta-androstan-3beta-ol-17-one + NADH + H+
? + NAD+
-
-
-
?
5beta-androstane-3alpha,17beta-diol + NAD+
?
-
-
-
?
5beta-androstane-3beta,17beta-diol + NAD+
?
-
-
-
?
5beta-dihydrotestosterone + NADH + H+
? + NAD+
-
-
-
?
5beta-pregnan-20alpha-ol-3-one + NAD+
5beta-pregnan-3,20-dione + NADH + H+
-
-
-
?
5beta-pregnan-3,20-dione + NAD(P)H + H+
3beta-hydroxy-5beta-pregnan-20-one + NAD(P)+
NADP+ is 3-5times less effective than NAD+
-
-
?
5beta-pregnan-3,20-dione + NADH
3beta-hydroxy-5beta-pregnan-20-one + NAD+
-
-
-
?
5beta-pregnan-3,20-dione + NADPH + H+
5beta-pregnane-3beta-ol-20-one + NADP+
5beta-pregnan-3beta,21-diol-20-one + NAD+
?
-
-
-
?
5beta-pregnan-3beta,21-diol-20-one + NADH + H+
? + NAD+
-
-
-
?
5beta-pregnan-3beta-ol-20-one + NAD(P)+
5-pregnan-3,20-dione + NAD(P)H + H+
NADP+ and NADPH are 3-5times less effective than NAD+ and NADH
-
-
r
5beta-pregnan-3beta-ol-20-one + NAD+
5beta-pregnan-3,20-dione + NADH + H+
-
-
-
?
alpha-3-hydroxyhexobarbital + NAD+
?
-
-
-
?
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
-
-
-
-
?
androst-4-ene-3,17-dione + NADPH + H+
testosterone + NADP+
androst-5-ene-3,11,17-trione + NADPH
17beta-hydroxyandrost-5-ene-3,11-dione + NADP+
androst-5-ene-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH
androstane-3,17-dione + NADPH
dihydrotestosterone + NADP+
-
-
-
-
?
androstanedione + NADPH
dihydrotestosterone + NADP+
-
reduction at C17
-
-
?
androstenediol + NAD(P)H + H+
testosterone + NAD(P)+
-
reaction catalysed by 3beta-HSD (type 1)
-
-
?
androstenedione + NAD(P)H + H+
testosterone + NAD(P)+
-
reaction catalysed by 17beta-HSD (type 1 and 3)
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
androsterone + NADPH + H+
5alpha-androstane-3alpha,17beta-diol + NADP+
androsterone + NADPH + H+
androstane-3beta,17beta-diol + NADP+
-
reduction at C17
-
-
?
beta-3-hydroxyhexobarbital + NAD+
?
-
-
-
?
beta-ionol + NAD+
(3E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one + NADH + H+
-
-
-
?
cis-benzene dihydrodiol + NAD+
?
-
-
-
?
cyclohexanol + NAD+
?
-
-
-
?
dehydroepiandrosterone + NAD(P)+
androst-5-en-3,17-dione + NAD(P)H + H+
dehydroepiandrosterone + NAD(P)H + H+
androstendiol + NAD(P)+
-
-
-
?
dehydroepiandrosterone + NAD(P)H + H+
androstenediol + NAD(P)+
-
reaction catalysed by 17beta-HSD (type 1 and 3)
-
-
?
dehydroepiandrosterone + NAD(P)H + H+
androstenedione + NAD(P)+
-
-
-
-
?
dehydroepiandrosterone + NAD+
4-androstene-3,17-dione + NADH + H+
dehydroepiandrosterone + NAD+
androstene-3,17-dione + NADH + H+
-
-
-
-
?
dehydroepiandrosterone + NADH + H+
? + NAD+
-
-
-
?
dehydroepiandrosterone + NADPH + H+
5-androstene-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH + H+
androst-5-ene-3beta,17beta-diol + NADP+
-
-
-
-
?
dihydroepiandrostendione + NADPH
dihydrotestosterone + NADP+
-
-
-
-
?
dihydrotestosterone + NAD+
5alpha-androstan-3,17-dione + NADH
-
-
-
-
r
dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
-
-
-
-
r
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
-
androsterone inactivation
-
-
?
epiandrosterone + NADPH
5-androstane-3beta,17beta-diol + NADP+
-
reduction at C17
-
-
?
epiandrosterone + NADPH
androstane-3beta,17beta-diol + NADP+
reduction at C17
-
-
?
estradiol + NAD(P)+
estrone + NAD(P)H
estradiol + NAD+
estrone + NADH
-
-
-
-
?
estradiol + NADP+
estrone + NADPH
estradiol sulfate + NADP+
estrone sulfate + NADPH
-
-
-
?
estrogenic estrone + NAD(P)H + H+
17beta-estradiol + NAD(P)+
the product 17beta-estradiol plays a central role in the etiology of estrogen dependent diseases
-
-
?
estrone + NAD(P)H + H+
17beta-estradiol + NAD(P)+
-
-
-
?
estrone + NAD(P)H + H+
estradiol + NAD(P)+
-
reaction catalysed by 17beta-HSD (type 1 and 3)
-
-
?
estrone + NADPH
estradiol + NADP+
-
estrogen activation
-
-
?
farnesol + NAD+
farnesal + NADH + H+
-
-
-
?
geraniol + NAD+
geranial + NADH + H+
-
-
-
?
geranylgeraniol + NAD+
geranylgeranial + NADH + H+
-
-
-
?
nerol + NAD+
neral + NADH + H+
-
-
-
?
pregnenolone + NAD(P)+
progesterone + NAD(P)H + H+
pregnenolone + NAD+
progesterone + NADH + H+
pregnenolone + NADP+
progesterone + NADPH + H+
-
-
-
-
?
pregnenolone + NADPH
progesterone + NADP+
-
-
-
-
?
pregnenolone + NADPH + H+
isoprogesterone + NADP+
testosterone + 3-acetylpyridine adenine dinucleotide
?
-
-
-
-
?
testosterone + 3-pyridinealdehyde adenine dinucleotide
?
-
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
testosterone + NAD(P)+
androstenedione + NAD(P)H + H+
testosterone + NAD+
4-androstenedione + NADH + H+
-
-
-
?
testosterone + NAD+
androst-4-en-3,17-dione + NADH + H+
-
-
-
-
r
testosterone + NAD+
androstenedione + NADH + H+
-
-
-
-
r
testosterone + NADP+
androst-4-en-3,17-dione + NADPH
-
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
testosterone + thionicotinamide adenine dinucleotide
?
-
-
-
-
?
trans-benzene dihydrodiol + NAD+
?
-
-
-
?
zymosterone + NADPH
zymosterol + NADP+
-
-
-
-
?
additional information
?
-
11beta-hydroxyandrost-5-ene-3,17-dione + NADPH
11beta,17beta-dihydroxyandrost-5-ene-3-one + NADP+
i.e. 11beta-hydroxy-androstenedione, reduction at C17
i.e. 11beta-testosterone
-
?
11beta-hydroxyandrost-5-ene-3,17-dione + NADPH
11beta,17beta-dihydroxyandrost-5-ene-3-one + NADP+
-
i.e. 11beta-hydroxy-androstenedione, reduction at C17
i.e. 11beta-testosterone
-
?
3beta-hydroxy-16alpha,17alpha-epoxypregn-5-en-20-one + NAD(P)+
?
-
-
-
-
?
3beta-hydroxy-16alpha,17alpha-epoxypregn-5-en-20-one + NAD(P)+
?
-
-
-
-
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
-
-
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
isozymes 17beta-HSD3 and 17beta-HSD5
-
-
r
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
selective reduction at C17
-
-
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstane-3,17-dione + NADPH + H+
-
-
-
-
r
5alpha-dihydrotestosterone + NADP+
5alpha-androstane-3,17-dione + NADPH + H+
-
-
-
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstane-3,17-dione + NADPH + H+
-
-
-
?
5beta-pregnan-3,20-dione + NADPH + H+
5beta-pregnane-3beta-ol-20-one + NADP+
-
-
-
?
5beta-pregnan-3,20-dione + NADPH + H+
5beta-pregnane-3beta-ol-20-one + NADP+
-
-
-
-
?
androst-4-ene-3,17-dione + NADPH + H+
testosterone + NADP+
-
-
-
?
androst-4-ene-3,17-dione + NADPH + H+
testosterone + NADP+
-
-
-
?
androst-4-ene-3,17-dione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
androst-5-ene-3,11,17-trione + NADPH
17beta-hydroxyandrost-5-ene-3,11-dione + NADP+
i.e. 11-keto-androstenedione, reduction at C17
i.e. 11-keto-testosterone
-
?
androst-5-ene-3,11,17-trione + NADPH
17beta-hydroxyandrost-5-ene-3,11-dione + NADP+
-
i.e. 11-ketoandrostenedione, reduction at C17
i.e. 11-keto-testosterone
-
?
androst-5-ene-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH
-
-
-
r
androst-5-ene-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH
-
-
-
r
androst-5-ene-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH
-
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
the forward reaction is preferred, no activity with NADH in the forward reaction, poor activity with NAD+ in the reverse raection, overview
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
the equilibrium state is 2% testosterone to 95% androstenedione
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
the forward reaction is preferred, no activity with NADH in the forward reaction, poor activity with NAD+ in the reverse raection, overview
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
isozymes 17beta-HSD1 and 17beta-HSD8
-
-
r
androsterone + NADPH + H+
5alpha-androstane-3alpha,17beta-diol + NADP+
-
-
-
?
androsterone + NADPH + H+
5alpha-androstane-3alpha,17beta-diol + NADP+
-
-
-
?
dehydroepiandrosterone + NAD(P)+
androst-5-en-3,17-dione + NAD(P)H + H+
-
-
-
-
?
dehydroepiandrosterone + NAD(P)+
androst-5-en-3,17-dione + NAD(P)H + H+
-
-
-
-
?
dehydroepiandrosterone + NAD(P)+
androst-5-en-3,17-dione + NAD(P)H + H+
-
-
-
-
?
dehydroepiandrosterone + NAD+
4-androstene-3,17-dione + NADH + H+
-
-
-
-
?
dehydroepiandrosterone + NAD+
4-androstene-3,17-dione + NADH + H+
-
-
-
-
?
dehydroepiandrosterone + NAD+
4-androstene-3,17-dione + NADH + H+
-
-
-
-
?
dehydroepiandrosterone + NADPH + H+
5-androstene-3beta,17beta-diol + NADP+
-
reduction at C17
-
-
?
dehydroepiandrosterone + NADPH + H+
5-androstene-3beta,17beta-diol + NADP+
reduction at C17
-
-
?
dehydroepiandrosterone + NADPH + H+
5-androstene-3beta,17beta-diol + NADP+
-
reduction at C17
-
-
?
estradiol + NAD(P)+
estrone + NAD(P)H
-
-
-
-
?
estradiol + NAD(P)+
estrone + NAD(P)H
-
-
-
-
?
estradiol + NADP+
estrone + NADPH
-
-
-
-
?
estradiol + NADP+
estrone + NADPH
-
-
-
r
estradiol + NADP+
estrone + NADPH
-
the equilibrium state is 3% estradiol and 97% estrone
-
-
r
estradiol + NADP+
estrone + NADPH
-
-
-
r
estradiol + NADP+
estrone + NADPH
-
-
-
r
pregnenolone + NAD(P)+
progesterone + NAD(P)H + H+
-
-
-
-
?
pregnenolone + NAD(P)+
progesterone + NAD(P)H + H+
-
-
-
-
?
pregnenolone + NAD(P)+
progesterone + NAD(P)H + H+
-
-
-
?
pregnenolone + NAD(P)+
progesterone + NAD(P)H + H+
-
-
-
-
?
pregnenolone + NAD+
progesterone + NADH + H+
-
-
-
-
?
pregnenolone + NAD+
progesterone + NADH + H+
-
the mitochondrial enzyme is essential for the synthesis of progesterone by corpora lutea, overview
-
-
?
pregnenolone + NAD+
progesterone + NADH + H+
-
-
-
-
?
pregnenolone + NADPH + H+
isoprogesterone + NADP+
-
-
-
?
pregnenolone + NADPH + H+
isoprogesterone + NADP+
-
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
r
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
-
r
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
-
r
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
-
-
-
-
?
testosterone + NAD(P)+
androstenedione + NAD(P)H + H+
-
-
-
-
?
testosterone + NAD(P)+
androstenedione + NAD(P)H + H+
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
-
r
additional information
?
-
the wild-type strain ATCC 119960 degrades steroids, such as testosterone, estradiol, or cholesterol, differences in the enzyme mutant strains, overview
-
-
?
additional information
?
-
the wild-type strain ATCC 119960 degrades steroids, such as testosterone, estradiol, or cholesterol, differences in the enzyme mutant strains, overview
-
-
?
additional information
?
-
evolutionary considerations
-
-
?
additional information
?
-
-
evolutionary considerations
-
-
?
additional information
?
-
no activity with androstanedione and androsterone
-
-
?
additional information
?
-
-
no activity with androstanedione and androsterone
-
-
?
additional information
?
-
-
activity of the enzyme is associated with the mechanism of prostatic regulation by androgens after castration, which is important in prostate cancer
-
-
?
additional information
?
-
-
evolutionary considerations
-
-
?
additional information
?
-
-
the enzyme is an important therapeutic target for androgen-sensitive diseases, overview
-
-
?
additional information
?
-
-
the isozyme 17beta-HSD3 is a critical determinant in steroid hormone biosynthesis
-
-
?
additional information
?
-
-
the isozyme might play an imporant role in modulation of active hormone levels in estrogen-sensitive cells or tissues
-
-
?
additional information
?
-
-
isozyme 17beta-HSD5 also shows 3alpha- and 20alpha-hydroxysteroid dehydrogenase, dihydrodiol dehydrogenase, and prostaglandin synthase activities
-
-
?
additional information
?
-
AKR1C3 physically interacts with the androgen receptor
-
-
?
additional information
?
-
-
AKR1C3 physically interacts with the androgen receptor
-
-
?
additional information
?
-
the enzyme AKR1C35 efficiently oxidizes various 3beta- and 17beta-hydroxysteroids, including biologically active 3beta-hydroxy-5alpha/beta-dihydro-C19/C21-steroids, dehydroepiandrosterone, and 17beta-estradiol, substrate specificity, detailed overview. Val54 plays a critical role in non-/recognition of the steroidal substrates. Reaction products identification by thin-layer chromatography (TLC) and liquid chromatography/mass spectrometry (LC/MS). No activity with 5beta-pregnan-3alpha-ol-20-one, 3alpha-hydroxyprogesterone, 5beta-androstan-3alpha-ol-17-one, 20alpha-hydroxyprogesterone, and 5alpha-pregnan-20alpha-ol-3-one
-
-
?
additional information
?
-
-
the enzyme AKR1C35 efficiently oxidizes various 3beta- and 17beta-hydroxysteroids, including biologically active 3beta-hydroxy-5alpha/beta-dihydro-C19/C21-steroids, dehydroepiandrosterone, and 17beta-estradiol, substrate specificity, detailed overview. Val54 plays a critical role in non-/recognition of the steroidal substrates. Reaction products identification by thin-layer chromatography (TLC) and liquid chromatography/mass spectrometry (LC/MS). No activity with 5beta-pregnan-3alpha-ol-20-one, 3alpha-hydroxyprogesterone, 5beta-androstan-3alpha-ol-17-one, 20alpha-hydroxyprogesterone, and 5alpha-pregnan-20alpha-ol-3-one
-
-
?
additional information
?
-
-
the enzyme plays a role in gonadal steroidogenesis
-
-
?
additional information
?
-
-
poor activity with estrone
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2,4-dihydroxyphenyl)-phenylmethanone
(3a,5a)-3-[[(2R,5S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]-2,5-dimethylpiperazin-1-yl]methyl]-17-methylideneandrostan-3-ol
-
-
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
-
i.e. RM-532-105
(3alpha,5alpha)-3-[(2,5-dimethyl-4-{[2-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)methyl]-3-hydroxyandrostan-17-one
the inhibitor RM-532-105 seems to have difficulties in penetrating inside the testis and is concentrated in the testicular capsule. Therefore it is unable to inhibit the 17bets-HSD3 located inside the testis. At a higher concentration, RM-532-105 significantly decreases the level of testosterone and dihydrotestosterone in rat plasma, in vivo effects of the inhibitor in testis and plasma, detailed overview
(4-(2,4-dichlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(2-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(2-methoxyphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(3-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-bromophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chloro-2-(hydroxymethyl)phenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chloro-2-methylphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorobenzoyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorobenzyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorophenyl)-1,4-diazepan-1-yl)(morpholino)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(1-oxido-4-thiomorpholino)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(4-methylpiperazin-1-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(cyclohexyl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanethione
-
(4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(phenyl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(piperidin-1-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(pyridin-4-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(thiomorpholino)methanone
-
(4-(4-ethynylphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-fluorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-iodophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-methoxyphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(6-bromopyridin-2-yl)piperazin-1-yl)(morpholino)methanone
-
(4-(6-chloropyridin-3-yl)piperazin-1-yl)(morpholino)methanone
-
(4-(biphenyl-4-yl)piperazin-1-yl)(morpholino)methanone
-
(5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(morpholino)methanone
-
1-(11,12-dihydro-6H-dibenzo[b,f]oxocin-12-yl)ethanone
-
IC50: 0.00297 mM
1-(4-(4-(4-chlorophenyl)piperazine-1-carbonyl)piperazin-1-yl)-2-hydroxyethanone
-
1-(4-(4-chlorophenyl)piperazine-1-carbonyl)piperidine-4-carboxylic acid
-
1-(5,6,11,12-tetrahydrodibenzo[b,f]azocin-12-yl)ethanone
-
IC50: 0.00474 mM
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]ethanone
-
IC50: 0.02 nM
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
-
IC50: 0.00024 mM; IC50: 0.00029 mM
11-[3-hydroxy-17-beta-hydroxyestr-5(10)-en-17alpha-yl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl]-undecanoic acid butyl-methyl-amide
-
selective inhibition of type 2 17beta-HSD
12-acetyl-1-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.0115 mM
12-acetyl-11,12-dihydro-2-(trifluoromethyl)-6H-dibenzo(b,f)(1,4)thiazocine
-
12-acetyl-11,12-dihydro-6H-dibenzo(b,f)(1,4)thiazocine
-
12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocin-3-ol
-
IC50: 0.0049 mM
12-acetyl-2,3-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00001 mM
12-acetyl-2-(trifluoromethyl)-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00281 mM
12-acetyl-2-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00003 mM
12-acetyl-3,4-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00076 mM
12-acetyl-3-bromo-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00025 mM
12-acetyl-3-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00010 mM
12-acetyl-3-fluoro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00009 mM
12-acetyl-3-methoxy-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.0021 mM
12-acetyl-3-methyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.001 mM
17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM
17alpha-ethynyl-estradiol
-
0.01 mM, 54% inhibition, reaction with 0.002 mM estradiol; inhibits oxidation of testosterone
17beta-dihydroequilin
-
0.01 mM, 88% inhibition, reaction with 0.002 mM estradiol
2,2',4,4'-tetrahydroxybenzophenone
remaining 17beta HSD3 activity: 47%
2,5-dioxo-3-(2-propyn-1-yl)-3-pyrrolidinecarboxylic acid 2,3,3-triphenyl-2-propen-1-yl-ester
-
2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-benzamide
-
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo(b,f)azocin-8-yl)-benzoic acid methyl ester
-
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 3 nM
2-hydroxy-estradiol
-
0.01 mM, 67% inhibition, reaction with 0.002 mM estradiol
20alpha-dihydroprogesterone
-
0.01 mM, 71% inhibition, reaction with 0.002 mM estradiol, inhibits oxidation of testosterone
3,4-dihydrobenzoic acid
-
0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione
3-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 3 nM
3-benzylidene camphor
remaining 17beta HSD3 activity: 56%
3-hydroxy-1,3,5(10)-estratriene-17beta-O,17alpha-butanolactone
-
selective for type 2 17beta-HSD versus types 1, 3, and 7 but not versus type 5 17beta-HSD
3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM; IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM
3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone
-
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase
3alpha-alkylated androsterone derivatives
-
17-88% inhibition at 0.003 mM, overview
-
3alpha-butyl-3-hydroxy-5alpha-androstan-17-one
-
3alpha-ether-3beta-substituted androsterone derivatives
-
diverse derivatives, IC50: 70-760 nM, overview
-
3beta-alkylated androsterone derivatives
-
IC50: 57-147 nM
-
3beta-cyclohexylethyl-androsterone
-
-
3beta-hexyl-androsterone
-
-
3beta-phenyl-androsterone
-
mixed-type inhibition, shows some proliferative activity on AR+ and Er+ cell lines not mediated through androgen or estrogen receptors
3beta-phenylethyl-3alpha-methyl-O-androsterone
-
IC50: 73 nM
3beta-phenylethyl-androsterone
3beta-phenylmethyl-androsterone
3beta-substituted androsterone derivatives
-
IC50: 57-147 nM
-
4-((4-(4-chlorophenyl)piperazin-1-yl)sulfonyl)morpholine
-
4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzoic acid
-
4-(4-chlorophenyl)-N-cyclohexylpiperazine-1-carboxamide
-
4-(4-chlorophenyl)-N-phenylpiperazine-1-carboxamide
-
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)-N-methylbenzamide
-
IC50: 25 nM
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 5 nM
4-methylbenzylidene camphor
remaining 17beta HSD3 activity: 33%
4-[4-(4-chlorophenyl)piperazine-1-carbonyl]-thiomorpholine-1,1-dione
-
5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00007 mM
5-acetyl-2-chloro-5,6-dihydro-dibenzo(b,f)azocine
-
5-acetyl-2-chloro-5,6-dihydrodibenzo[b,f]azocine
-
IC50: 0.00024 mM
5-acetyl-2-chloro-8-(2-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 3 nM
5-acetyl-2-chloro-8-(3-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 8 nM
5-acetyl-2-chloro-8-(4-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 2 nM
5-acetyl-2-chloro-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 4 nM
5-acetyl-3-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00005 mM
5-acetyl-5,6,11,12-tetrahydro-dibenzo(b,f)(1,4)diazocine
-
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
-
IC50: 0.00049 mM
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine-9-carboxamide
-
IC50: 0.001 mM
5-acetyl-8-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 9 nM
5-acetyl-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.02 nM
5-acetyl-9-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 7 nM
5-acetyl-N-cyclohexyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
-
IC50: 8 nM
5alpha-androstane-3alpha,17beta-diol
-
0.01 mM, 87% inhibition, reaction with 0.002 mM estradiol
5alpha-dihydrotestosterone
-
inhibits oxidation of testosterone
5beta-androstane-3alpha,17beta-diol
-
0.01 mM, 83% inhibition, reaction with 0.002 mM estradiol
5beta-dihydrotestosterone
-
inhibits oxidation of testosterone
9-bromo-11,12-dihydrodibenzo[b,f]azocine-5(6H)-carboxamide
-
IC50: 0.00028 mM
9-bromo-5-butanoyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00032 mM
9-bromo-5-ethyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.001 mM
beta-octylglucoside
-
strong
chloromercuribenzene-p-sulfonic acid
-
-
danazol
-
inhibits oxidation of testosterone, 0.01 mM, 83% inhibition
dibenzothiazocine
-
IC50: 0.0004 mM
dodecyl-beta-D-maltoside
-
inhibition above 0.5%
EM-919
-
a 17beta-HSD type 2 inhibitor
estradiol
-
inhibits oxidation of testosterone
estrone
substrate inhibition
gallic acid
-
0.001 mM, 50% inhibition, reduction of androst-4-en-3,17-dione
GTx-560
competitively and selectively inhibits AKR1C3-dependent androgen receptor transactivation. GTx-560 completely blocks the formation of testosterone from androstenedione, indicating the ability of AKR1C3 inhibitors, unlike 5alpha-reductase inhibitors, to reduce testosterone levels
methyl 12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine-3-sulfinate
-
IC50: 0.01 mM
methyl 3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.00004 mM
methyl 4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzoate
-
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.00004 mM; IC50: 0.7 nM
methyl [3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
-
IC50: 0.00014 mM
methyl [4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
-
IC50: 2 nM
morpholino(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
-
morpholino(4-(4-nitrophenyl)piperazin-1-yl)methanone
-
morpholino(4-(naphthalen-2-yl)piperazin-1-yl)methanone
-
morpholino(4-(o-tolyl)piperazin-1-yl)methanone
-
morpholino(4-(p-tolyl)piperazin-1-yl)methanone
-
morpholino(4-(quinolin-3-yl)piperazin-1-yl)methanone
-
morpholino(4-phenylpiperazin-1-yl)methanone
-
-
morpholino-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
-
N,N-dimethyl-4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
N-(((3,5)-3-hydroxy-17-oxoandrostan-3-yl)methyl)-N-(tricyclo(3.3.1.13.7)dec-2-ylmethyl)butanamide
-
N-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl)acetamide
-
N-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl)methanesulfonamide
-
N-(5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-yl)benzamide
-
IC50: 0.00016 mM
N-methyl-4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
oleuropein glycoside
-
0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione
Perfluorooctanoic acid
-
-
spiro-gamma-lactone-estradiol
-
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM
spironolactone
-
IC50 for oxidation of testosterone: 0.0011 mM
testosterone
-
0.01 mM, 70% inhibition, reaction with 0.002 mM estradiol
tetrahydrodibenzazocine
-
IC50: 0.00009 mM
[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanol
-
IC50: 0.9 nM
(2,4-dihydroxyphenyl)-phenylmethanone
remaining 17beta HSD3 activity: 1.1%
(2,4-dihydroxyphenyl)-phenylmethanone
-
(2,4-dihydroxyphenyl)-phenylmethanone leads to inhibition of testosterone synthesis in freshly isolated mouse and rat testis tissue
(2,4-dihydroxyphenyl)-phenylmethanone
-
(2,4-dihydroxyphenyl)-phenylmethanone leads to inhibition of testosterone synthesis in freshly isolated mouse and rat testis tissue
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
-
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
-
D-5-2
3beta-phenylethyl-androsterone
-
IC50: 99 nM
3beta-phenylethyl-androsterone
-
-
3beta-phenylmethyl-androsterone
-
IC50: 57 nM
3beta-phenylmethyl-androsterone
-
mixed-type inhibition, shows some proliferative activity on AR+ and Er+ cell lines not mediated through androgen or estrogen receptors
9-cis-retinoic acid
-
weak
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
RM-532-105
-
RM-532-105
-
3beta-(o-trifluoromethylphenyl-sulfonyl-dimethylpipera-zino)-androsterone, a 3 beta-dimethylpiperazino-ADT sulfonamide derivative. RM-532-105 is a better competitor of labeled enzyme substrate [14C]-4-dione than the unlabeled natural substrate 4-dione (IC50 = 341 and 337 nM) used itself as an inhibitor
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.212 mg/ml result in 50% enzyme inhibition
-
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.4 mg/ml result in 50% enzyme inhibition
-
Triton X-100
-
significant
additional information
-
synthesis, inhibitory potency, and in vivo effects of the diverse inhibitor derivatives, detailed overview
-
additional information
-
design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-HSD, the bisubstrate inhibitors are less potent in intact cells than in homogenated cells, overview, the best inhibitors of that series are those bearing an alkyl side-chain spacer of 11 or 12 methylenes with inhibition of 69% and 78% at 1 mM
-
additional information
high-throughput screening, a series of non-carboxylate morpholino(phenylpiperazin-1-yl)methanones are prepared by palladium-catalysed coupling of substituted phenyl or pyridyl bromides with morpholino(piperazin-1-yl)methanone, and are shown to be potent and very isoform-selective inhibitors of AKR1C3, competitive fluorescence assay, structure-activity relationships, overview
-
additional information
small-molecule inhibitors inhibit both the enzymatic and coactivator functions of AKR1C3 resulting in androgen-dependent prostate cancer and CRPC regression. No inhibition by indomethacin
-
additional information
-
small-molecule inhibitors inhibit both the enzymatic and coactivator functions of AKR1C3 resulting in androgen-dependent prostate cancer and CRPC regression. No inhibition by indomethacin
-
additional information
17beta-HSD1 and 17beta-HSD2 inhibitor structures and their biological activities are reviewed
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.028
(R)-1,2,3,4-tetrahydro-1-naphthol
pH 7.4, 25°C, recombinant enzyme
0.0015
(S)-1,2,3,4-tetrahydro-1-naphthol
pH 7.4, 25°C, recombinant enzyme
0.0012
(S)-1-indanol
pH 7.4, 25°C, recombinant enzyme
0.023
1-Acenaphthenol
pH 7.4, 25°C, recombinant enzyme
0.0004
17beta-estradiol
pH 7.4, 25°C, recombinant enzyme
0.026
2-Cyclohexen-1-ol
pH 7.4, 25°C, recombinant enzyme
0.00053
20alpha-dihydroprogesterone
-
pH 7.4, with NAD+ as cofactor
0.685
3-acetylpyridine adenine dinucleotide
-
testosterone as substrate
0.063
3-pyridinealdehyde adenine dinucleotide
-
testosterone as substrate
0.0009
3beta-hydroxyprogesterone
pH 7.4, 25°C, recombinant enzyme
0.0081
4-androstene-3alpha,17beta-diol
pH 7.4, 25°C, recombinant enzyme
0.642
5-androsten-3beta-ol-17-one
50°C, pH 7.8
0.0033
5-androstene-3beta,17beta-diol
pH 7.4, 25°C, recombinant enzyme
0.09
5-pregnen-3beta-ol-20-one
50°C, pH 7.8
0.068 - 0.176
5alpha-Androst-16-en-3-one
0.0025
5alpha-Androstan-3beta-ol-17-one
pH 7.4, 25°C, recombinant enzyme
0.0076 - 0.2
5alpha-dihydrotestosterone
0.106
5alpha-pregnan-3,20-dione
50°C, pH 7.8
0.0039 - 0.116
5alpha-pregnan-3beta-ol-20-one
0.046
5beta-androstan-3beta-ol-17-one
pH 7.4, 25°C, recombinant enzyme
0.0039
5beta-androstane-3alpha,17beta-diol
pH 7.4, 25°C, recombinant enzyme
0.015
5beta-androstane-3beta,17beta-diol
pH 7.4, 25°C, recombinant enzyme
0.013
5beta-dihydrotestosterone
pH 7.4, 25°C, recombinant enzyme
0.21 - 1.725
5beta-pregnan-3,20-dione
0.015
5beta-pregnan-3beta,21-diol-20-one
pH 7.4, 25°C, recombinant enzyme
0.0068 - 0.314
5beta-Pregnan-3beta-ol-20-one
0.014
alpha-3-hydroxyhexobarbital
pH 7.4, 25°C, recombinant enzyme
0.04
beta-3-hydroxyhexobarbital
pH 7.4, 25°C, recombinant enzyme
0.001
beta-ionol
pH 7.4, 25°C, recombinant enzyme
0.0097
cis-benzene dihydrodiol
pH 7.4, 25°C, recombinant enzyme
0.074
Cyclohexanol
pH 7.4, 25°C, recombinant enzyme
0.00001 - 0.0043
dehydroepiandrosterone
0.00025
dihydrotestosterone
-
pH 7.4, with NAD+ as cofactor
0.00035
estradiol
-
pH 7.4, with NAD+ as cofactor
0.0012
farnesol
pH 7.4, 25°C, recombinant enzyme
0.0041
geraniol
pH 7.4, 25°C, recombinant enzyme
0.001
geranylgeraniol
pH 7.4, 25°C, recombinant enzyme
0.011
nerol
pH 7.4, 25°C, recombinant enzyme
0.00067
pregnenolone
-
pH and temperature not specified in the publication
0.00061 - 0.31
testosterone
0.083
Thionicotinamide adenine dinucleotide
-
testosterone as substrate
0.011
trans-benzene dihydrodiol
pH 7.4, 25°C, recombinant enzyme
additional information
additional information
-
0.068
5alpha-Androst-16-en-3-one
-
microsomal enzyme
0.107
5alpha-Androst-16-en-3-one
-
mitochondrial enzyme
0.176
5alpha-Androst-16-en-3-one
-
cytosolic enzyme
0.0076
5alpha-dihydrotestosterone
pH 7.4, 25°C, recombinant enzyme
0.14
5alpha-dihydrotestosterone
-
-
0.2
5alpha-dihydrotestosterone
-
cofactor NAD+ or NADP+
0.0039
5alpha-pregnan-3beta-ol-20-one
pH 7.4, 25°C, recombinant enzyme
0.116
5alpha-pregnan-3beta-ol-20-one
50°C, pH 7.8
0.21
5beta-pregnan-3,20-dione
-
-
1.725
5beta-pregnan-3,20-dione
50°C, pH 7.8
0.0068
5beta-Pregnan-3beta-ol-20-one
pH 7.4, 25°C, recombinant enzyme
0.314
5beta-Pregnan-3beta-ol-20-one
50°C, pH 7.8
0.00001
dehydroepiandrosterone
-
37°C, pH not specified in the publication
0.0043
dehydroepiandrosterone
pH 7.4, 25°C, recombinant enzyme
0.023
NAD+
pH 7.4, 25°C, with substrate S-tetralol
0.083
NAD+
-
testosterone as substrate
0.11
NAD+
-
pH 7.4, reaction with estradiol
0.167
NAD+
-
pH 7.4, reaction with testosterone
0.0053
NADH
-
pH 7.4, reaction with 4-dionetestosterone
0.0056
NADH
-
pH 7.4, reaction with estronel
0.017
NADH
pH 7.4, 25°C, with substrate S-camphorquinone
0.0082
NADP+
-
testosterone as substrate, 17beta-hydroxysteroid dehydrogenase activity
0.009
NADP+
-
3beta-hydroxy-5alpha-androstan-17-one as substrate, 3beta-hydroxysteroid dehydrogenase activity
2.4
NADP+
pH 7.4, 25°C, with substrate S-camphorquinone
9.6
NADP+
-
pH 7.4, reaction with estradiol
0.0018
NADPH
-
5alpha-dihydrotestosterone as substrate, 3-beta-hydroxysteroid dehydrogenase activity
0.0021
NADPH
-
estrone as substrate, 17beta-hydroxysteroid dehydrogenase activity
0.00061
testosterone
-
pH 7.4, with NAD+ as cofactor
0.0081
testosterone
pH 7.4, 25°C, recombinant enzyme
0.2
testosterone
-
cofactor NAD+ or NADP+
0.24
testosterone
-
NADP+ as variable substrate
additional information
additional information
Michaelis-Menten kinetics
-
additional information
additional information
-
Michaelis-Menten kinetics
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.001
(2,4-dihydroxyphenyl)-phenylmethanone
Homo sapiens
pH 7.4, 37°C
0.000262
(3a,5a)-3-[[(2R,5S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]-2,5-dimethylpiperazin-1-yl]methyl]-17-methylideneandrostan-3-ol
Homo sapiens
-
pH and temperature not specified in the publication
0.000085
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00297
1-(11,12-dihydro-6H-dibenzo[b,f]oxocin-12-yl)ethanone
Homo sapiens
-
IC50: 0.00297 mM
0.00474
1-(5,6,11,12-tetrahydrodibenzo[b,f]azocin-12-yl)ethanone
Homo sapiens
-
IC50: 0.00474 mM
0.000037 - 0.000051
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
Rattus norvegicus
-
pH 7.4, 37°C
0.00000002
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]ethanone
Homo sapiens
-
IC50: 0.02 nM
0.00024 - 0.00029
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
0.0115
12-acetyl-1-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.0115 mM
0.00281
12-acetyl-11,12-dihydro-2-(trifluoromethyl)-6H-dibenzo(b,f)(1,4)thiazocine
Homo sapiens
pH and temperature not specified in the publication
0.0004
12-acetyl-11,12-dihydro-6H-dibenzo(b,f)(1,4)thiazocine
Homo sapiens
pH and temperature not specified in the publication
0.0049
12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocin-3-ol
Homo sapiens
-
IC50: 0.0049 mM
0.00001
12-acetyl-2,3-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00001 mM
0.00281
12-acetyl-2-(trifluoromethyl)-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00281 mM
0.00003
12-acetyl-2-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00003 mM
0.00076
12-acetyl-3,4-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00076 mM
0.00025
12-acetyl-3-bromo-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00025 mM
0.0001
12-acetyl-3-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00010 mM
0.00009
12-acetyl-3-fluoro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00009 mM
0.0021
12-acetyl-3-methoxy-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.0021 mM
0.001
12-acetyl-3-methyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.001 mM
0.0009
17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM
0.0181
2,2',4,4'-tetrahydroxybenzophenone
Homo sapiens
pH 7.4, 37°C
0.00915
2,5-dioxo-3-(2-propyn-1-yl)-3-pyrrolidinecarboxylic acid 2,3,3-triphenyl-2-propen-1-yl-ester
Homo sapiens
pH and temperature not specified in the publication
0.00006
2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-benzamide
Homo sapiens
pH and temperature not specified in the publication
0.00000002
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo(b,f)azocin-8-yl)-benzoic acid methyl ester
Homo sapiens
pH and temperature not specified in the publication
0.000003
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
Homo sapiens
-
IC50: 3 nM
0.000003
3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
Homo sapiens
-
IC50: 3 nM
0.033
3-benzylidene camphor
Homo sapiens
pH 7.4, 37°C
0.001
3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM
0.001
3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM
0.0011 - 0.0014
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
0.0007
3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone
Homo sapiens
-
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase
0.000116
3alpha-butyl-3-hydroxy-5alpha-androstan-17-one
Homo sapiens
pH and temperature not specified in the publication
0.00007 - 0.00076
3alpha-ether-3beta-substituted androsterone derivatives
Homo sapiens
-
diverse derivatives, IC50: 70-760 nM, overview
-
0.000057 - 0.000147
3beta-alkylated androsterone derivatives
Homo sapiens
-
IC50: 57-147 nM
-
0.000073
3beta-phenylethyl-3alpha-methyl-O-androsterone
Homo sapiens
-
IC50: 73 nM
0.000099
3beta-phenylethyl-androsterone
Homo sapiens
-
IC50: 99 nM
0.000057
3beta-phenylmethyl-androsterone
Homo sapiens
-
IC50: 57 nM
0.000057 - 0.000147
3beta-substituted androsterone derivatives
Homo sapiens
-
IC50: 57-147 nM
-
0.000025
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)-N-methylbenzamide
Homo sapiens
-
IC50: 25 nM
0.000005
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
Homo sapiens
-
IC50: 5 nM
0.00000145
4-MA
Homo sapiens
-
37°C, pH not specified in the publication
0.0107
4-methylbenzylidene camphor
Homo sapiens
pH 7.4, 37°C
0.00007
5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00007 mM
0.00024
5-acetyl-2-chloro-5,6-dihydro-dibenzo(b,f)azocine
Homo sapiens
pH and temperature not specified in the publication
0.00024
5-acetyl-2-chloro-5,6-dihydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00024 mM
0.000003
5-acetyl-2-chloro-8-(2-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 3 nM
0.000008
5-acetyl-2-chloro-8-(3-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 8 nM
0.000002
5-acetyl-2-chloro-8-(4-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 2 nM
0.000004
5-acetyl-2-chloro-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 4 nM
0.00005
5-acetyl-3-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00005 mM
0.00474
5-acetyl-5,6,11,12-tetrahydro-dibenzo(b,f)(1,4)diazocine
Homo sapiens
pH and temperature not specified in the publication
0.00049
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
Homo sapiens
-
IC50: 0.00049 mM
0.001
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine-9-carboxamide
Homo sapiens
-
IC50: 0.001 mM
0.000009
5-acetyl-8-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 9 nM
0.00000002
5-acetyl-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.02 nM
0.000007
5-acetyl-9-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 7 nM
0.000008
5-acetyl-N-cyclohexyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
Homo sapiens
-
IC50: 8 nM
0.00092
7-hydroxyflavone
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.00028
9-bromo-11,12-dihydrodibenzo[b,f]azocine-5(6H)-carboxamide
Homo sapiens
-
IC50: 0.00028 mM
0.00032
9-bromo-5-butanoyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00032 mM
0.001
9-bromo-5-ethyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.001 mM
0.000337 - 0.000341
androstenedione
Rattus norvegicus
-
pH 7.4, 37°C
0.000182
androsterone
Homo sapiens
pH and temperature not specified in the publication
0.001
chrysin
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.00015
cyproterone acetate
Homo sapiens
-
37°C, pH not specified in the publication
0.0004
dibenzothiazocine
Homo sapiens
-
IC50: 0.0004 mM
0.0000062
epostane
Homo sapiens
-
37°C, pH not specified in the publication
0.005
galangin
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.0042
genistein
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.0065
Hexestrol
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.05
hinokitiol
Mesocricetus auratus
above, pH 7.4, 25°C, recombinant enzyme
0.0044
lithocholic acid
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.01
methyl 12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine-3-sulfinate
Homo sapiens
-
IC50: 0.01 mM
0.00004
methyl 3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
Homo sapiens
-
IC50: 0.00004 mM
0.0000007 - 0.00004
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
0.00014
methyl [3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
Homo sapiens
-
IC50: 0.00014 mM
0.000002
methyl [4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
Homo sapiens
-
IC50: 2 nM
0.000035
N-(((3,5)-3-hydroxy-17-oxoandrostan-3-yl)methyl)-N-(tricyclo(3.3.1.13.7)dec-2-ylmethyl)butanamide
Homo sapiens
pH and temperature not specified in the publication
0.00016
N-(5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-yl)benzamide
Homo sapiens
-
IC50: 0.00016 mM
0.0177 - 0.194
Perfluorooctanoic acid
0.05
Phenolphthalein
Mesocricetus auratus
above, pH 7.4, 25°C, recombinant enzyme
0.0026
quercetin
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.000026 - 0.0001
RM-532-105
0.00025
spiro-gamma-lactone-estradiol
Homo sapiens
-
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM
0.0011
spironolactone
Homo sapiens
-
IC50 for oxidation of testosterone: 0.0011 mM
0.00009
tetrahydrodibenzazocine
Homo sapiens
-
IC50: 0.00009 mM
0.015
zearalenone
Mesocricetus auratus
pH 7.4, 25°C, recombinant enzyme
0.0000009
[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanol
Homo sapiens
-
IC50: 0.9 nM
0.00024
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
Homo sapiens
-
IC50: 0.00024 mM
0.00029
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
Homo sapiens
-
IC50: 0.00029 mM
0.0011
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM
0.0014
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM
0.0000007
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
Homo sapiens
-
IC50: 0.7 nM
0.00004
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
Homo sapiens
-
IC50: 0.00004 mM
0.0177
Perfluorooctanoic acid
Rattus norvegicus
-
testicular microsome, inhibition of 17beta-hydroxysteroid dehydrogenase, pH and temperature not specified in the publication
0.0532
Perfluorooctanoic acid
Rattus norvegicus
-
testicular microsome, pH and temperature not specified in the publication, inhibition of 3beta-hydroxysteroid dehydrogenase
0.146
Perfluorooctanoic acid
Rattus norvegicus
-
intact Leydig cells, pH and temperature not specified in the publication, inhibition of 3beta-hydroxysteroid dehydrogenase
0.194
Perfluorooctanoic acid
Rattus norvegicus
-
intact Leydig cells, inhibition of 17beta-hydroxysteroid dehydrogenase, pH and temperature not specified in the publication
0.000026
RM-532-105
Rattus norvegicus
-
pH 7.4, 37°C, inhibition in recombinant HEK-293 cells overexpressing 17 beta-HSD3, overview
0.0001
RM-532-105
Rattus norvegicus
-
pH 7.4, 37°C, inhibition in wild-type rat testis, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
drug target
the ratio of HSD17B1 to HSD17B2 is a good indicator of tamoxifen treatment benefit, as post-menopausal patients with tumors expressing a high HSD17B1/HSD17B2 protein ratio have less benefit from tamoxifen treatment
evolution
3,17beta-hydroxysteroid dehydrogenase is a member of the short-chain dehydrogenase/reductase (SDR) superfamily
evolution
enzyme AKR1C35 is a member of the aldoÂketo reductase (AKR) 1C subfamily in the AKR superfamily
evolution
-
enzyme Tsol-17betaHSD belongs to the short-chain dehydrogenase/reductase (SDR) protein superfamily, it shares motifs and activity with the type 3 enzyme of some other species
evolution
the enzyme belongs to the AKR1C family
evolution
-
all three proteins (Rdh11/12-like 1-3) include conserved signatures of the SDR family, such as cofactor binding (TGXXXGXG), the catalytic mechanism (YXXXK), and the structural integrity (NVG or NAG) patterns. Japanese eel Rdh11/12-like 1 clusters with piscine Rdh11 and Rdh12, but the cluster is formed outside that of mammalian Rdh11 and Rdh12. In contrast, Rdh11/12-like 2 and Rdh11/12-like 3 form a clade with putative European eel Rdh11s and Rdh12s outside that of mammalian and piscine Rdh11/Rdh12
evolution
-
3,17beta-hydroxysteroid dehydrogenase is a member of the short-chain dehydrogenase/reductase (SDR) superfamily
-
malfunction
AKR1C3 siRNA reduces androgen receptor signaling in VCaP cells. Small-molecule inhibitors inhibit both the enzymatic and coactivator functions of AKR1C3 resulting in androgen-dependent prostate cancer and CRPC regression
malfunction
compared to the wild-type Comamonas testosteroni, degradation ability of testosterone and cholesterol is almost lost, and degradation of estradiol is decreased in the 3,17beta-HSD knockout mutant. Degradation of testosterone and cholesterol is obviously increased in the 3,17beta-HSD overexpression mutant. The growths in the medium with testosterone, cholesterol or estradiol are impaired in 3,17beta-HSD knockout mutant
malfunction
mutation of Val54Ala, but not Cys310Phe, significantly impairs the 3beta-hydroxysteroid dehydrogenase enzyme activity, suggesting that Val54 plays a critical role in recognition of the steroidal substrate
malfunction
knockdown of 17beta-HSD1 gene, HSD17B1, modulates the transcript profile of the hormone-dependent breast cancer cell line T47D, T47D, with 105 genes regulated 1.5 fold or higher in estradiol-independent manner
malfunction
knockdown of 17beta-HSD1 gene, HSD17B1, modulates the transcript profile of the hormone-dependent breast cancer cell line T47D, with 105 genes regulated 1.5fold or higher in estradiol-independent manner. Genes that are primarily involved in the cell cycle progression, such as the cyclin A2 gene, CCNA2, are generally down-regulated whereas genes involved in apoptosis and cell death, including the pro-apoptotic gene XAF1, IFIH1 and FGF12, are upregulated by 17beta-HSD1 knockdown
malfunction
-
compared to the wild-type Comamonas testosteroni, degradation ability of testosterone and cholesterol is almost lost, and degradation of estradiol is decreased in the 3,17beta-HSD knockout mutant. Degradation of testosterone and cholesterol is obviously increased in the 3,17beta-HSD overexpression mutant. The growths in the medium with testosterone, cholesterol or estradiol are impaired in 3,17beta-HSD knockout mutant
-
metabolism
Comamonas testosteroni strain ATCC11996 is a gram-negative bacterium which can use steroids as carbon and energy source. 3,17beta-HSD is an enzyme which is involved in the complete oxidative degradation of the steroid skeleton, induced in the presence of these compounds in the culture medium
metabolism
the enzyme catalyzes the last step in the biosynthesis of the potent androgen testosterone (T), by stereoselectively reducing the C17 ketone of 4-androstene-3,17-dione (4-dione), with NADPH as cofactor
metabolism
the enzyme catalyzes the last step in the biosynthesis of the potent androgen testosterone (T), by stereoselectively reducing the C17 ketone of 4-androstene-3,17-dione (4-dione), with NADPH as cofactor
metabolism
HSD17B1 is controlled by estradiol, dihydrotestosterone, and miRNAs, as well as modulated by several breast cancer related genes
metabolism
the enzyme catalyses the last step in estrogen activation
metabolism
-
the enzyme is important in all basic steroidogenic pathways
metabolism
-
the enzyme catalyzes the last step in the biosynthesis of the potent androgen testosterone (T), by stereoselectively reducing the C17 ketone of 4-androstene-3,17-dione (4-dione), with NADPH as cofactor
-
metabolism
-
Comamonas testosteroni strain ATCC11996 is a gram-negative bacterium which can use steroids as carbon and energy source. 3,17beta-HSD is an enzyme which is involved in the complete oxidative degradation of the steroid skeleton, induced in the presence of these compounds in the culture medium
-
physiological function
key enzyme in cardenolide biosynthesis
physiological function
-
17beta-hydroxysteroid dehydrogenase type 3 catalyzes the last step in the biosynthesis of the potent androgen testosterone by stereoselectively reducing the C17 ketone of 4-androstene-3,17-dione (4-dione), with NADPH as cofactor
physiological function
-
17beta-hydroxysteroid dehydrogenases (17beta-HSD) are key enzymes involved in the formation (reduction) and inactivation (oxidation) of sex steroids. Taenia solium cysticerci are able to synthesize sex steroid hormones in vitro when precursors are provided in the culture medium
physiological function
3,17beta-hydroxysteroid dehydrogenase is a key enzyme in steroid degradation
physiological function
castration-resistant prostate cancer may occur by several mechanisms including the upregulation of androgen receptor, coactivators, and steroidogenic enzymes, including aldo keto reductase 1C3 (AKR1C3). AKR1C3 converts weaker 17-keto androgenic precursors to more potent 17-hydroxy androgens and is consistently the major upregulated gene in castration-resistant prostate cancer, CRPC. AKR1C3 enhances androgen signaling and prostate cancer xenograft growth. AKR1C3 is a receptor- and tissue-selective pharmacologically targetable coactivator that promotes prostate cancer growth, AKR1C3-dependent R1881-induced androgen receptor transactivation in HEK-293 cells
physiological function
-
conversion of testosterone to 4-dione detected in abdominal adipose tissue is caused by 17beta-HSD type 2 which is localized in the vasculature of the adipose compartment
physiological function
enzyme AKR1C35 oxidizes various xenobiotic alicyclic alcohols using NAD+
physiological function
17beta-HSD1 may be involved in oncogenesis by favoring antiapoptosis pathway in breast cancer cells
physiological function
-
Japanese eel retinol dehydrogenases 11/12-like 1-3 (Rdh11/12-like 1-3, EC 1.1.1.300) are 17-oxosteroid reductases involved in sex steroid synthesis. Catalysis of the conversion of A4 to T and E1 to E2 is performed by recombinant Rdh11/12-like 1
physiological function
the enzyme 17beta-HSD1 may be involved in oncogenesis by favoring antiapoptosis pathway in breast cancer cells and correborates with its previously shown role in increasing breast cancer cell proliferation. The gene regulation occurring in steroid-deprived conditions shows that 17beta-HSD1 can modulate endogenous gene expression in steroid-independent manners
physiological function
the enzyme increases breast cancer cell proliferation via a dual effect on 17-beta-estradiol and 5alpha-dihydrotestosterone levels and impacts gene expression and protein profile of breast cancer cells cultured in 17-beta-estradiol-contained medium
physiological function
the enzyme is involved in estrogen-dependent diseases
physiological function
the expression of 17beta-hydroxysteroid dehydrogenase 1 and 2 alone and in combination predicts outcome of patients with breast cancer
physiological function
-
3,17beta-hydroxysteroid dehydrogenase is a key enzyme in steroid degradation
-
physiological function
-
key enzyme in cardenolide biosynthesis
-
additional information
PhaR is a repressor that controls 3,17beta-HSD expression, phaR knock-out mutants grow at higher rates and produce more protein in the presence of steroids as carbon source. PhaR also regulates other genes that relate to steroid degradation. Estradiol and cholesterol both cannot induce betahsd gene expression in both wild-type and mutant Comamonas testosteroni
additional information
-
PhaR is a repressor that controls 3,17beta-HSD expression, phaR knock-out mutants grow at higher rates and produce more protein in the presence of steroids as carbon source. PhaR also regulates other genes that relate to steroid degradation. Estradiol and cholesterol both cannot induce betahsd gene expression in both wild-type and mutant Comamonas testosteroni
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Dahm, K.; Breuer, H.
Anreicherung einer 17beta-hydroxysteroid: NAD(P)-Oxydoreduktase aus der Nebenniere der Ratte
Hoppe-Seyler's Z. Physiol. Chem.
336
63-68
1964
Rattus norvegicus, Rattus norvegicus Wistar
-
brenda
Mulder, E.; Lamers-Stahlhofen, G.J.M.; van der Molen, H.J.
Isolation and characterization of 17beta-hydroxy steroid dehydrogenase from human erythrocytes
Biochem. J.
127
649-659
1972
Homo sapiens
brenda
Heyns, W.; de Moor, P.
A 3(17)beta-hydroxysteroid dehydrogenase in rat erythrocytes. Conversion of 5alpha-dihydrotestosterone into 5alpha-androstane-3beta,17beta-diol and purification of the enzyme by affinity chromatography
Biochim. Biophys. Acta
358
1-13
1974
Rattus norvegicus, Rattus norvegicus Wistar
brenda
Schultz, R.M.; Groman, E.V.; Engel, L.L.
3(17)beta-Hydroxysteroid dehydrogenase of Pseudomonas testosteroni. Ligand binding properties
J. Biol. Chem.
252
3784-3790
1977
Comamonas testosteroni
brenda
Schultz, R.M.; Groman, E.V.; Engel, L.L.
3(17)beta-Hydroxysteroid dehydrogenase of Pseudomonas testosteroni. A convenient purification and demonstration of multiple molecular forms
J. Biol. Chem.
252
3775-3783
1977
Comamonas testosteroni
brenda
Shen, C.C.; Kochakian, C.D.
The induction, purification and characterization of 17beta-hydroxy-C19-steroid dehydrogenase of the female guinea pig kidney
J. Steroid Biochem.
10
187-193
1979
Cavia porcellus
brenda
Kwan, T.K.; Gower, D.B.
Kinetic studies of 3alpha- and 3beta-hydroxysteroid dehydrogenase in neonatal porcine testis subcellular fractions
Biochem. Soc. Trans.
12
842-843
1984
Sus scrofa
-
brenda
Minard, P.; Legoy, M.D.; Thomas, D.
3beta, 17beta-Hydroxysteroid dehydrogenase of Pseudomonas testosteroni. Kinetic evidence for the bifunctional activity at a common catalytic site
FEBS Lett.
188
85-90
1985
Comamonas testosteroni
brenda
Stokes, N.A.; Hylemon, P.B.
Characterization of DELTA4-3-ketosteroid-5beta-reductase and 3beta-hydroxysteroid dehydrogenase in cell extracts of Clostridium innocuum
Biochim. Biophys. Acta
836
255-261
1985
[Clostridium] innocuum
brenda
Benach, J.; Knapp, S.; Oppermann, UC.; Hagglund, O.; Jornvall, H.; Ladenstein, R.
Crystallization and crystal packing of recombinant 3 (or 17) beta-hydroxysteroid dehydrogenase from Comamonas testosteroni ATTC 11996
Eur. J. Biochem.
236
144-148
1996
Comamonas testosteroni, Comamonas testosteroni ATTC 11996
brenda
Stevenson, D.; Kochakian, C.D.
Purification of male guinea pig kidney 17beta-hydroxy-C19-steroid dehydrogenase
Endocrinology
95
766-770
1974
Cavia porcellus
brenda
Khan, N.; Sharma, K.K.; Andersson, S.; Auchus, R.J.
Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells
Arch. Biochem. Biophys.
429
50-59
2004
Homo sapiens
brenda
Benach, J.; Filling, C.; Oppermann, U.C.; Roversi, P.; Bricogne, G.; Berndt, K.D.; Jornvall, H.; Ladenstein, R.
Structure of bacterial 3beta/17beta-hydroxysteroid dehydrogenase at 1.2 A resolution: a model for multiple steroid recognition
Biochemistry
41
14659-14668
2002
Comamonas testosteroni (P19871), Comamonas testosteroni
brenda
Poirier, D.
Inhibitors of 17beta-hydroxysteroid dehydrogenases
Curr. Med. Chem.
10
453-477
2003
Homo sapiens, Rattus norvegicus
brenda
Lu, M.L.; Huang, Y.W.; Lin, S.X.
Purification, reconstitution, and steady-state kinetics of the trans-membrane 17beta-hydroxysteroid dehydrogenase 2
J. Biol. Chem.
277
22123-22130
2002
Homo sapiens
brenda
Tchedam Ngatcha, B.; Luu-The, V.; Labrie, F.; Poirier, D.
Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship
J. Med. Chem.
48
5257-5268
2005
Homo sapiens
brenda
Mindnich, R.; Haller, F.; Halbach, F.; Moeller, G.; Hrabe de Angelis, M.; Adamski, J.
Androgen metabolism via 17beta-hydroxysteroid dehydrogenase type 3 in mammalian and non-mammalian vertebrates: comparison of the human and the zebrafish enzyme
J. Mol. Endocrinol.
35
305-316
2005
Danio rerio (Q6QA32), Danio rerio, Homo sapiens
brenda
Liu, H.; Robert, A.; Luu-The, V.
Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme
J. Steroid Biochem. Mol. Biol.
94
173-179
2005
Homo sapiens
brenda
Durocher, F.; Sanchez, R.; Ricketts, M.L.; Labrie, Y.; Laudet, V.; Simard, J.
Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/DELTA5-DELTA4-isomerase expressed in the adrenal gland and gonads
J. Steroid Biochem. Mol. Biol.
97
289-298
2005
Cavia porcellus
brenda
Ngatcha, B.T.; Laplante, Y.; Labrie, F.; Luu-The, V.; Poirier, D.
3beta-Alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines
Mol. Cell. Endocrinol.
248
225-232
2006
Homo sapiens
brenda
Luu-The, V.; Tremblay, P.; Labrie, F.
Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women
Mol. Endocrinol.
20
437-443
2006
Homo sapiens
brenda
Fink, B.E.; Gavai, A.V.; Tokarski, J.S.; Goyal, B.; Misra, R.; Xiao, H.; Kimball, S.D.; Han, W.; Norris, D.; Spires, T.E.; You, D.; Gottardis, M.M.; Lorenzi, M.V.; Vite, G.D.
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
Bioorg. Med. Chem. Lett.
16
1532-1536
2006
Homo sapiens
brenda
Degtyar, V.G.; Babkina, T.V.; Kazantseva, I.A.; Morozov, A.P.; Trapeznikova, M.F.; Kushlinskii, N.E.
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure
Bull. Exp. Biol. Med.
139
715-717
2005
Homo sapiens
brenda
Ulrih, N.P.; Lanisnik Rizner, T.
Conformational stability of 17 beta-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus
FEBS J.
273
3927-3937
2006
Curvularia lunata
brenda
Zhou, L.Y.; Wang, D.S.; Senthilkumaran, B.; Yoshikuni, M.; Shibata, Y.; Kobayashi, T.; Sudhakumari, C.C.; Nagahama, Y.
Cloning, expression and characterization of three types of 17beta-hydroxysteroid dehydrogenases from the Nile tilapia, Oreochromis niloticus
J. Mol. Endocrinol.
35
103-116
2005
Oreochromis niloticus
brenda
Lukacik, P.; Kavanagh, K.L.; Oppermann, U.
Structure and function of human 17beta-hydroxysteroid dehydrogenases
Mol. Cell. Endocrinol.
248
61-71
2006
Homo sapiens
brenda
Chapman, J.C.; Polanco, J.R.; Min, S.; Michael, S.D.
Mitochondrial 3 beta-hydroxysteroid dehydrogenase (HSD) is essential for the synthesis of progesterone by corpora lutea: an hypothesis
Reprod. Biol. Endocrinol.
3
11
2005
Mus musculus
brenda
Aizawa, K.; Iemitsu, M.; Maeda, S.; Jesmin, S.; Otsuki, T.; Mowa, C.N.; Miyauchi, T.; Mesaki, N.
Expression of steroidogenic enzymes and synthesis of sex steroid hormones from DHEA in skeletal muscle of rats
Am. J. Physiol.
292
E577-E584
2007
Rattus norvegicus
brenda
Arukwe, A.; Nordtug, T.; Kortner, T.M.; Mortensen, A.S.; Brakstad, O.G.
Modulation of steroidogenesis and xenobiotic biotransformation responses in zebrafish (Danio rerio) exposed to water-soluble fraction of crude oil
Environ. Res.
107
362-370
2008
Danio rerio (Q7ZZC3)
brenda
Prisco, M.; Liguoro, A.; Ricchiari, L.; Del Giudice, G.; Angelini, F.; Andreuccetti, P.
Immunolocalization of 3beta-HSD and 17beta-HSD in the testis of the spotted ray Torpedo marmorata
Gen. Comp. Endocrinol.
155
157-163
2008
Torpedo marmorata
brenda
Chen, G.; Bourneuf, E.; Marklund, S.; Zamaratskaia, G.; Madej, A.; Lundstroem, K.
Gene expression of 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase in relation to androstenone, testosterone, and estrone sulphate in gonadally intact male and castrated pigs
J. Anim. Sci.
85
2457-2463
2007
Sus scrofa
brenda
Luu-The, V.; Ferraris, C.; Duche, D.; Belanger, P.; Leclaire, J.; Labrie, F.
Steroid metabolism and profile of steroidogenic gene expression in Episkin: high similarity with human epidermis
J. Steroid Biochem. Mol. Biol.
107
30-36
2007
Homo sapiens
brenda
Herl, V.; Frankenstein, J.; Meitinger, N.; Mueller-Uri, F.; Kreis, W.
Delta5-3beta-hydroxysteroid dehydrogenase (3betaHSD) from Digitalis lanata. Heterologous expression and characterisation of the recombinant enzyme
Planta Med.
73
704-710
2007
Digitalis lanata (Q93Y47), Digitalis lanata
brenda
Parthasarathy, C.; Balasubramanian, K.
Assessment of in vitro effects of metyrapone on Leydig cell steroidogenesis
Steroids
73
328-338
2008
Rattus norvegicus
brenda
Hunter, A.C.; Coyle, E.; Morse, F.; Dedi, C.; Dodd, H.T.; Koussoroplis, S.J.
Transformation of 5-ene steroids by the fungus Aspergillus tamarii KITA: Mixed molecular fate in lactonization and hydroxylation pathways with identification of a putative 3beta-hydroxy-steroid dehydrogenase/DELTA(5)-DELTA(4) isomerase pathway
Biochim. Biophys. Acta
1791
110-117
2008
Aspergillus tamarii, Aspergillus tamarii KITA
brenda
Higo, S.; Hojo, Y.; Ishii, H.; Kominami, T.; Nakajima, K.; Poirier, D.; Kimoto, T.; Kawato, S.
Comparison of sex-steroid synthesis between neonatal and adult rat hippocampus
Biochem. Biophys. Res. Commun.
385
62-66
2009
Rattus norvegicus
brenda
Bruzzone, F.; Rego, J.L.; Luu-The, V.; Pelletier, G.; Vallarino, M.; Vaudry, H.
Immunohistochemical localization and biological activity of 3beta-hydroxysteroid dehydrogenase and 5alpha-reductase in the brain of the frog, Rana esculenta, during development
J. Chem. Neuroanat.
39
35-50
2010
Pelophylax lessonae
brenda
Senthilkumaran, B.; Sudhakumari, C.C.; Wang, D.S.; Sreenivasulu, G.; Kobayashi, T.; Kobayashi, H.K.; Yoshikuni, M.; Nagahama, Y.
Novel 3beta-hydroxysteroid dehydrogenases from gonads of the Nile tilapia: phylogenetic significance and expression during reproductive cycle
Mol. Cell. Endocrinol.
299
146-152
2009
Oreochromis niloticus (B9UN12), Oreochromis niloticus (B9UN14)
brenda
Chura, J.C.; Ryu, H.S.; Simard, M.; Poirier, D.; Tremblay, Y.; Brooker, D.C.; Blomquist, C.H.; Argenta, P.A.
Steroid-converting enzymes in human ovarian carcinomas
Mol. Cell. Endocrinol.
301
51-58
2009
Homo sapiens
brenda
Nashev, L.G.; Schuster, D.; Laggner, C.; Sodha, S.; Langer, T.; Wolber, G.; Odermatt, A.
The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals
Biochem. Pharmacol.
79
1189-1199
2010
Mus musculus, Rattus norvegicus, Homo sapiens (P37058), Homo sapiens
brenda
Darvas, B.; Székács, A.; Fónagy, A.; Szécsi, M.; Tóth, I.
Progesterone in Periplaneta americana and Neobellieria bullata adults from the procuticle phase until first progeny production
Gen. Comp. Endocrinol.
107
450-460
1997
Periplaneta americana
brenda
Tóth, I.; Szécsi, M.; Julesz, J.; Faredin, I.; Behnke, B.
In vitro inhibition of testicular delta 5-3 beta-hydroxysteroid dehydrogenase and prostatic 5 alpha-reductase activities in rats and humans by strogen forte extract
Int. Urol. Nephrol.
28
337-348
1996
Homo sapiens, Rattus norvegicus, Rattus norvegicus Wistar
brenda
Zhao, B.; Chu, Y.; Hardy, D.O.; Li, X.K.; Ge, R.S.
Inhibition of 3beta- and 17beta-hydroxysteroid dehydrogenase activities in rat Leydig cells by perfluorooctane acid
J. Steroid Biochem. Mol. Biol.
118
13-17
2010
Rattus norvegicus
brenda
De Catalfo, G.; De Alaniz, M.; Marra, C.
Influence of commercial dietary oils on lipid composition and testosterone production in interstitial cells isolated from rat testis
Lipids
44
345-357
2009
Rattus norvegicus
brenda
Ernst, M.; de Padua, R.M.; Herl, V.; Mueller-Uri, F.; Kreis, W.
Expression of 3beta-HSD and P5betaR, genes respectively coding for Delta5-3beta-hydroxysteroid dehydrogenase and progesterone 5beta-reductase, in leaves and cell cultures of Digitalis lanata EHRH
Planta Med.
76
923-927
2010
Digitalis lanata (Q93Y47), Digitalis lanata
brenda
Tóth, I.; Szécsi, M.; Julesz, J.; Faredin I.
Activity and inhibition of 3-beta-hydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin
Skin Pharmacol. Physiol.
10
160-168
1997
Homo sapiens
brenda
Svegelj, M.B.; Stojan, J.; Rizner, T.L.
The role of Ala231 and Trp227 in the substrate specificities of fungal 17beta-hydroxysteroid dehydrogenase and trihydroxynaphthalene reductase: Steroids versus smaller substrates
J. Steroid Biochem. Mol. Biol.
129
92-98
2012
Curvularia lunata
brenda
Kenmogne, L.C.; Maltais, R.; Poirier, D.
Synthesis of a dansyl-labeled inhibitor of 17beta-hydroxysteroid dehydrogenase type 3 for optical imaging
Bioorg. Med. Chem. Lett.
26
2179-2183
2016
Homo sapiens
brenda
Flanagan, J.U.; Atwell, G.J.; Heinrich, D.M.; Brooke, D.G.; Silva, S.; Rigoreau, L.J.; Trivier, E.; Turnbull, A.P.; Raynham, T.; Jamieson, S.M.; Denny, W.A.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-beta-hydroxysteroid dehydrogenase (AKR1C3)
Bioorg. Med. Chem.
22
967-977
2014
Homo sapiens (P42330)
brenda
Yu, Y.; Liu, C.; Wang, B.; Li, Y.; Zhang, H.
Characterization of 3,17beta-hydroxysteroid dehydrogenase in Comamonas testosteroni
Chem. Biol. Interact.
234
221-228
2015
Comamonas testosteroni (P19871), Comamonas testosteroni ATCC 119960 (P19871)
brenda
Li, M.; Xiong, G.; Maser, E.
A novel transcriptional repressor PhaR for the steroid-inducible expression of the 3,17beta-hydroxysteroid dehydrogenase gene in Comamonas testosteroni ATCC11996
Chem.-Biol. Interact.
202
116-125
2013
Comamonas testosteroni (P19871), Comamonas testosteroni ATCC 119960 (P19871)
brenda
Yepuru, M.; Wu, Z.; Kulkarni, A.; Yin, F.; Barrett, C.M.; Kim, J.; Steiner, M.S.; Miller, D.D.; Dalton, J.T.; Narayanan, R.
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth
Clin. Cancer Res.
19
5613-5625
2013
Homo sapiens (P42330), Homo sapiens
brenda
Aceves-Ramos, A.; de la Torre, P.; Hinojosa, L.; Ponce, A.; García-Villegas, R.; Laclette, J.P.; Bobes, R.J.; Romano, M.C.
Cloning, characterization and functional expression of Taenia solium 17 beta-hydroxysteroid dehydrogenase
Gen. Comp. Endocrinol.
203
186-192
2014
Taenia solium
brenda
Endo, S.; Noda, M.; Ikari, A.; Tatematsu, K.; El-Kabbani, O.; Hara, A.; Kitade, Y.; Matsunaga, T.
Characterization of hamster NAD+-dependent 3(17)beta-hydroxysteroid dehydrogenase belonging to the aldo-keto reductase 1C subfamily
J. Biochem.
158
425-434
2015
Mesocricetus auratus (A0A097ZMZ1), Mesocricetus auratus
brenda
Roy, J.; Fournier, M.A.; Maltais, R.; Kenmogne, L.C.; Poirier, D.
In vitro and in vivo evaluation of a 3beta-androsterone derivative as inhibitor of 17beta-hydroxysteroid dehydrogenase type 3
J. Steroid Biochem. Mol. Biol.
141
44-51
2014
Rattus norvegicus
brenda
Roy, J.; Fournier, M.A.; Maltais, R.; Kenmogne, L.C.; Poirier, D.
Reprint of in vitro and in vivo evaluation of a 3beta-androsterone derivative as inhibitor of 17beta-hydroxysteroid dehydrogenase type 3
J. Steroid Biochem. Mol. Biol.
153
170-178
2015
Rattus norvegicus (O54939), Homo sapiens (P37058), Rattus norvegicus Sprague-Dawley (O54939)
brenda
Mansour, M.F.; Pelletier, M.; Boulet, M.-M.; Mayrand, D.; Brochu, G.; Lebel, S.; Poirier, D.; Fradette, J.; Cianflone, K.; Luu-The, V.; Tchernof, A.
Oxidative activity of 17beta-hydroxysteroid dehydrogenase on testosterone in male abdominal adipose tissues and cellular localization of 17beta-HSD type 2
Mol. Cell. Endocrinol.
414
168-176
2015
Homo sapiens
brenda
Li, T.; Stephen, P.; Zhu, D.W.; Shi, R.; Lin, S.X.
Crystal structures of human 17beta-hydroxysteroid dehydrogenase type 1 complexed with estrone and NADP+ reveal the mechanism of substrate inhibition
FEBS J.
286
2155-2166
2019
Homo sapiens (P14061)
brenda
Suzuki, H.; Ozaki, Y.; Gen, K.; Kazeto, Y.
Japanese eel retinol dehydrogenases 11/12-like are 17-ketosteroid reductases involved in sex steroid synthesis
Gen. Comp. Endocrinol.
305
113685
2021
Anguilla japonica
brenda
Fernández-Cabezón, L.; Galán, B.; García, J.
Engineering Mycobacterium smegmatis for testosterone production
Microb. Biotechnol.
10
151-161
2017
Curvularia lunata, Comamonas testosteroni (P19871), Comamonas testosteroni ATCC 11996 (P19871)
brenda
Aka, J.; Calvo, E.; Lin, S.
Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1
Mol. Cell. Endocrinol.
439
175-186
2017
Homo sapiens (P14061)
brenda
Salah, M.; Abdelsamie, A.S.; Frotscher, M.
Inhibitors of 17?-hydroxysteroid dehydrogenase type 1, 2 and 14 Structures, biological activities and future challenges
Mol. Cell. Endocrinol.
489
66-81
2019
Homo sapiens (P14061)
brenda
Hilborn, E.; Stal, O.; Jansson, A.
Estrogen and androgen-converting enzymes 17beta-hydroxysteroid dehydrogenase and their involvement in cancer with a special focus on 17beta-hydroxysteroid dehydrogenase type 1, 2, and breast cancer
Oncotarget
8
30552-30562
2017
Homo sapiens (P14061)
brenda
Hilborn, E.; Stal, O.; Alexeyenko, A.; Jansson, A.
The regulation of hydroxysteroid 17beta-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer
Oncotarget
8
62183-62194
2017
Homo sapiens (P14061)
brenda
Emanuelsson, I.; Almokhtar, M.; Wikvall, K.; Groenbladh, A.; Nylander, E.; Svensson, A.L.; Fex Svenningsen, A.; Norlin, M.
Expression and regulation of CYP17A1 and 3?-hydroxysteroid dehydrogenase in cells of the nervous system Potential effects of vitamin D on brain steroidogenesis
Neurochem. Int.
113
46-55
2018
Rattus norvegicus
brenda